Baumann P - Search Results

1

Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.

Conus P, Bondolfi G, Eap CB, Macciardi F, Baumann P. Conus P, et al. Among authors: baumann p. Pharmacopsychiatry. 1996 May;29(3):108-10. doi: 10.1055/s-2007-979554. Pharmacopsychiatry. 1996. PMID: 8738315

2

Probable metabolic interaction between methadone and fluvoxamine in addict patients.

Bertschy G, Baumann P, Eap CB, Baettig D. Bertschy G, et al. Among authors: baumann p. Ther Drug Monit. 1994 Feb;16(1):42-5. doi: 10.1097/00007691-199402000-00006. Ther Drug Monit. 1994. PMID: 8160253

3

Fluoxetine addition to methadone in addicts: pharmacokinetic aspects.

Bertschy G, Eap CB, Powell K, Baumann P. Bertschy G, et al. Among authors: baumann p. Ther Drug Monit. 1996 Oct;18(5):570-2. doi: 10.1097/00007691-199610000-00008. Ther Drug Monit. 1996. PMID: 8885121

4

Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.

Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Bondolfi G, et al. Among authors: baumann p. Psychopharmacology (Berl). 1996 Dec;128(4):421-5. doi: 10.1007/s002130050152. Psychopharmacology (Berl). 1996. PMID: 8986013 Clinical Trial.

5

Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine.

Eap CB, Lima CA, Macciardi F, Woggon B, Powell K, Baumann P. Eap CB, et al. Among authors: baumann p. Ther Drug Monit. 1998 Feb;20(1):7-13. doi: 10.1097/00007691-199802000-00002. Ther Drug Monit. 1998. PMID: 9485547

6

Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.

Baumann P, Broly F, Kosel M, Eap CB. Baumann P, et al. Pharmacopsychiatry. 1998 Mar;31(2):72. doi: 10.1055/s-2007-979303. Pharmacopsychiatry. 1998. PMID: 9562213 No abstract available.

7

Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.

Eap CB, Bertel-Laubscher R, Zullino D, Amey M, Baumann P. Eap CB, et al. Among authors: baumann p. Pharmacopsychiatry. 2000 May;33(3):112-5. doi: 10.1055/s-2000-7975. Pharmacopsychiatry. 2000. PMID: 10855463

8

Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.

Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M, Baumann P. Eap CB, et al. Among authors: baumann p. J Clin Psychopharmacol. 2001 Jun;21(3):330-4. doi: 10.1097/00004714-200106000-00013. J Clin Psychopharmacol. 2001. PMID: 11386497 Clinical Trial.

9

The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.

Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P. Bondolfi G, et al. Among authors: baumann p. Pharmacopsychiatry. 2002 Mar;35(2):50-6. doi: 10.1055/s-2002-25026. Pharmacopsychiatry. 2002. PMID: 11985287 Clinical Trial.

10

Clinical relevance of phenotyping groups of patients for psychotropic drug trials.

Baumann P, Eap CB. Baumann P, et al. Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:86A-87A. doi: 10.1097/00002826-199201001-00046. Clin Neuropharmacol. 1992. PMID: 1499008 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

967 results

Search Page

Filters